Preclinical biotech Lento Bio raises $680,000 in oversubscribed seed round

Funding will advance small molecule therapeutics that tackle molecular damage and remove Advanced Glycation End Products.

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Funding will advance small molecule therapeutics that tackle molecular damage and remove Advanced Glycation End Products.

Lento Bio, a preclinical pharmaceutical company developing small-molecule therapeutics to restore ocular lens flexibility and near-vision in presbyopia patients, has announced it has raised $680,000 in funding during their recent oversubscribed seed round.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

LTUI: 2489

Lento Bio

Longevity level(s):

  • Level 6: Aging disease prevention therapeutics
    Therapeutic interventions that control aging drivers to prevent aging diseases from occurring, like the current wave of GLP-1 agonists that prevent type 2 diabetes through metabolic interventions that also are proving effective in mitigating cardiovascular and neurological diseases.
  • Level 7: Targeted aging disease reversal
    Therapeutic interventions that stop or reverse age-related damage in specific organs (organ specific / tissue specific / localized reversal) or for age-related diseases including technologies like partial cellular reprogramming.

Overview

Lento Bio is a preclinical-stage biopharmaceutical company developing small-molecule therapeutics targeting molecular damage associated with aging. The company focuses on inhibiting advanced glycation end products (AGEs) and other long-lived protein damage modalities to address age-related diseases, with an initial emphasis on presbyopia through topical eyedrop formulations. Lento Bio's approach aims to reverse tissue stiffening and restore physiological function by directly addressing the underlying mechanisms of aging-related decline, with plans to expand into systemic age-related diseases following validation in ocular indications.

Access all data points on DLT:

  • Financial Data
  • Patents
  • Technology
  • Management
  • Advisory Board
  • News
  • Classifications
  • Similar Companies
Expand

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Oyster surfaces with $60m and a tau degrader that travels light

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE